Literature DB >> 32489221

Case-only trees and random forests for exploring genotype-specific treatment effects in randomized clinical trials with dichotomous endpoints.

James Y Dai1, Michael LeBlanc2.   

Abstract

Discovering gene-treatment interactions in clinical trials is of rising interest in the era of precision medicine. Nonparametric statistical learning methods such as trees and random forests are useful tools for building prediction rules. In this article, we introduce trees and random forests to the recently proposed case-only approach for discovering gene-treatment interactions and estimating marker-specific treatment effects for a dichotomous trial endpoints. The motivational example is a case-control genetic association study in the Prostate Cancer Prevention Trial (PCPT), which tested the hypothesis whether finasteride can prevent prostate cancer. We compare this novel approach to the interaction tree method previously proposed. Because of the modeling simplicity - directly targeting at interaction - and the statistical efficiency of the case-only approach, case-only trees and random forests yield more accurate prediction of heterogeneous treatment effects and better measure of variable importance, relative to the interaction tree method which uses data from both cases and controls. Application of the proposed case-only trees and random forests to the PCPT study yielded a discovery of genotypes that may influence the prevention effect of finasteride.

Entities:  

Keywords:  case-only methods; gene-treatment interaction; individualized treatment effects; precision medicine; subgroups

Year:  2019        PMID: 32489221      PMCID: PMC7266264          DOI: 10.1111/rssc.12366

Source DB:  PubMed          Journal:  J R Stat Soc Ser C Appl Stat        ISSN: 0035-9254            Impact factor:   1.864


  19 in total

1.  Pharmacogenomics--drug disposition, drug targets, and side effects.

Authors:  William E Evans; Howard L McLeod
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

2.  The challenge of subgroup analyses--reporting without distorting.

Authors:  Stephen W Lagakos
Journal:  N Engl J Med       Date:  2006-04-20       Impact factor: 91.245

3.  Case-only analysis of treatment-covariate interactions in clinical trials.

Authors:  E Vittinghoff; D C Bauer
Journal:  Biometrics       Date:  2006-09       Impact factor: 2.571

4.  Two-stage testing procedures with independent filtering for genome-wide gene-environment interaction.

Authors:  James Y Dai; Charles Kooperberg; Michael Leblanc; Ross L Prentice
Journal:  Biometrika       Date:  2012-09-25       Impact factor: 2.445

5.  Random forests of interaction trees for estimating individualized treatment effects in randomized trials.

Authors:  Xiaogang Su; Annette T Peña; Lei Liu; Richard A Levine
Journal:  Stat Med       Date:  2018-04-29       Impact factor: 2.373

6.  Subgroup identification from randomized clinical trial data.

Authors:  Jared C Foster; Jeremy M G Taylor; Stephen J Ruberg
Journal:  Stat Med       Date:  2011-08-04       Impact factor: 2.373

7.  Subgroup analysis and other (mis)uses of baseline data in clinical trials.

Authors:  S F Assmann; S J Pocock; L E Enos; L E Kasten
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

8.  Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies.

Authors:  W W Piegorsch; C R Weinberg; J A Taylor
Journal:  Stat Med       Date:  1994-01-30       Impact factor: 2.373

9.  Transition of a clinical trial into translational research: the prostate cancer prevention trial experience.

Authors:  Phyllis J Goodman; Catherine M Tangen; Alan R Kristal; Ian M Thompson; M Scott Lucia; Elizabeth A Platz; William D Figg; Ashraful Hoque; Ann Hsing; Marian L Neuhouser; Howard L Parnes; Juergen K V Reichardt; Regina M Santella; Cathee Till; Scott M Lippman
Journal:  Cancer Prev Res (Phila)       Date:  2010-12

10.  The influence of finasteride on the development of prostate cancer.

Authors:  Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2003-06-24       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.